Last year was dominated by the weakening financial markets and cash-strapped biotechs trying to find alternative sources of capital. But 2008 still managed to produce uniquely structured biopharma partnerships and groundbreaking takeovers that moved acquirers into new businesses. Below we focus below on the dealmakers, showing which companies dominated the dealmaking landscape in terms of volume, as well as the therapeutic areas that grabbed the most attention.
Amanda Micklus and Beth Detuzzi
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
